Semaglutide and tirzepatide are both GLP-1 based medications that work through the same biological pathway
This means its involved in numerous cellular functions, from gene expression to cell growth, making it a cornerstone of overall cellular, metabolic, and reproductive health
A lapsed $250 CAD patent and expired data exclusivity opened Canada's market years before US patents expire in 2032
In these cases, prioritizing the site with the most subcutaneous fat, often the abdomen, even in lean individuals, produces the most comfortable experience
Research shows that approximately 12 percent of patients pause or discontinue GLP-1 treatment due to digestive discomfort
Consult your physician to see if Semaglutide is right for you